NCT05191186View on ClinicalTrials.gov

Documentation of Efficacy of Intralymphatic Allergen Immunotherapy

PHASE3CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

August 1, 2023

Study Completion Date

December 31, 2023

Conditions
Allergic Rhinitis Due to Grass PollenAllergic Conjunctivitis of Both EyesAllergic Asthma
Interventions
DRUG

Grass pollen extract - Alutard Phleum pratense, ALK

injection in lymph node

Trial Locations (2)

8200

Aarhus University Hospital, Aarhus

58183

Linkoeping University Hospital, Linköping

All Listed Sponsors
collaborator

University of Aarhus

OTHER

collaborator

University Hospital, Linkoeping

OTHER

lead

Aarhus University Hospital

OTHER

NCT05191186 - Documentation of Efficacy of Intralymphatic Allergen Immunotherapy | Biotech Hunter | Biotech Hunter